advertisement
Abstract #6482 Published in IGR 3-2
A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension
Aung T; Chew PTK; Yip CC; Chan YH; See JLS; Khng CG; Hoh ST; Ng LH; Lee HMAmerican Journal of Ophthalmology 2001; 131: 636-642
PURPOSE: To compare the intraocular (IOP)-lowering effect and side-effects of latanoprost 0.005% once daily with unoprostone 0.12% twice daily. METHODS: Sixty patients with primary open-angle glaucoma (POAG) or ocular hypertension were randomized to receive either latanoprost once daily in the evening and placebo once daily in the morning, or unoprostone twice daily in the morning and evening. The study was double masked and followed a crossover design with two treatment periods of one month separated by a three-week washout period. IOP was measured at 9 a.m. and 5 p.m. on the baseline and day 28 visits, and at 9 a.m. on the day 2 and 14 visits of each treatment period. The 9 a.m. measurement was taken two hours and 13 hours after the last drop of unoprostone and latanoprost, and the 5 p.m. measurement was at ten and 21 hours, respectively. The mean of the measurements was calculated. Safety parameters were also recorded. RESULTS: Fifty-six patients completed both treatment periods and had IOP data available of revaluation. After one month of treatment, latanoprost significantly reduced IOP (mean ± SEM) by 6.1 ± 0.5 mmHg (p < 0.001) and unoprostone by 4.2 ± 0.4 mmHg (p < 0.001), adjusted from an overall baseline of 22.3 ± 0.5 and 23.2 ± 0.4 mmHg, respectively. The difference of 1.9 mmHg between treatments was statistically significant in favor of latanoprost (p = 0.003, analysis of covariance). Unadjusted analysis of responders using the percentage decrease in IOP showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group. Adverse ocular symptoms and findings were mild in both treatment groups. Eye redness and ocular irritation were the most frequently reported events. CONCLUSIONS: Latanoprost once daily was significantly more effective in reducing IOP compared with unoprostone twice daily after one month of treatment in patients with POAG and ocular hypertension. Both drugs were well tolerated with few ocular adverse events.
Dr P.T.K. Chew, Department of Ophthalmology, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074. ophchewp@nus.edu.sg
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
